Scandion Oncology

What Scandion Oncology does

Scandion Oncology A/S is a clinical-stage biotechnology company founded in 2017 as a spin-out from the University of Copenhagen and Saniona AB to address cancer drug resistance. Its core technology is a drug efflux pump inhibition technique that biomodulates the ABCG2 and UGT1A1 targets to block active drug efflux from cancer cells and re-sensitize resistant tumors to standard chemotherapy. The lead compound SCO-101 is an oral, once-daily small molecule positioned as first-in-class, and was advanced through two clinical programs: the Phase 2 CORIST trial combining SCO-101 with FOLFIRI chemotherapy in metastatic colorectal cancer patients with acquired resistance, and the Phase 1 PANTAX program for pancreatic cancer. The pipeline is supported by a proprietary drug screening platform designed to identify compounds that overcome cancer drug resistance, and the IP estate includes a granted EU combination patent (valid to May 2037) and a pending Composition of Matter application with a favorable EPO opinion that, if granted, could extend protection to at least 2042.

The business model was a classic pre-revenue biotech play: cash burn was funded through successive equity raises — an SEK ~26M IPO on Spotlight Stock Market in 2018 (later moved to Nasdaq First North Growth Market Sweden under ticker SCOL in February 2021), a SEK ~29.3M rights issue in 2019, and an SEK ~75M rights issue in July 2022 — supplemented by non-dilutive grants (Innovation Fund Denmark, Eurostars, EISMEA). Commercial pricing does not exist; the intended path to revenue was out-licensing or an asset sale of SCO-101 to a pharmaceutical partner at an appropriate value inflection point. Active business-development outreach targeted the JP Morgan Healthcare Conference and bio-partnering events.

As of March 27, 2025, the Annual General Meeting resolved on voluntary solvent liquidation under Chapter 14 of the Danish Companies Act. Nasdaq Stockholm approved delisting with the last trading day set for July 11, 2025, and the appointed liquidator is targeting final asset distribution in H2 2025. The company is headquartered at Symbion, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark, and operated with 1–10 employees. Headcount had effectively been depleted through a series of 2022–2023 leadership transitions (CEO Bo Rode Hansen's August 2022 departure, COO Maj Hedtjärn's resignation, and the subsequent appointments of Francois Martelet as CEO, Jan Stenvang as CSO, and Peter Høngaard Andersen as Chairman) ahead of the wind-down.

Name

Scandion Oncology

Legal name

Scandion Oncology A/S

Website

https://scandiononcology.com

Company type

Public

Founded year

2017

Operating status

Closed

Headcount range

1–10 employees

Short description

Scandion Oncology is a Copenhagen-based clinical-stage biotech developing SCO-101, a first-in-class small molecule that inhibits ABCG2/UGT1A1 drug efflux pumps to reverse cancer chemotherapy resistance, with its lead Phase 2 program in metastatic colorectal cancer.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• Cancer drug resistance
• Oncology drug development
• Clinical stage biotech
• Drug efflux inhibition
• Combination chemotherapy

Headquarters

HQ city

Københoved

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

1. Pharmaceutical Licensing/Asset Sale: Pre-revenue clinical-stage biotech company. Future revenue expected through out-licensing or selling SCO-101 asset to pharmaceutical companies at appropriate value inflection points. Business development activities initiated to introduce SCO-101 program to pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Scandion Oncology develops SCO-101, a first-in-class oral drug candidate that uses a drug efflux pump inhibition technique with biomodulation capabilities targeting ABCG2 and UGT1A1 to revert cancer drug resistance. The lead asset was studied in the Phase 2 CORIST trial in metastatic colorectal cancer in combination with FOLFIRI chemotherapy and in the Phase 1 PANTAX program for pancreatic cancer. The intended commercial path is out-licensing or asset sale of SCO-101 to pharmaceutical companies at an appropriate value inflection point.

Product overview

Scandion Oncology is a clinical-stage biotech company that has developed a unified portfolio centered on its lead compound SCO-101, a first-in-class drug candidate targeting cancer drug resistance. The company's technology platform employs drug efflux pump inhibition with biomodulation capabilities on ABCG2 and UGT1A1 targets. SCO-101 is the core product being advanced through two clinical programs: the CORIST Phase 2 trial for metastatic colorectal cancer and the PANTAX Phase 1 program for pancreatic cancer. The company is based in Copenhagen, Denmark, and was listed on Nasdaq First North Growth Market Sweden.

Differentiator

Problem solved

Functional benefit

Products and services

• SCO-101 First-in-class oral drug candidate that uses a drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert cancer drug resistance; being developed for use in combination with standard chemotherapies such as FOLFIRI and taxanes.

Quantifiable outcome

• Phase II CORIST trial demonstrated safety and tolerability of SCO-101 in combination with FOLFIRI
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Solural PharmacoreStrategic or Co-development Partner · 1 May 2019Contract signed with Solural Pharma to formulate SCO-101 tablets for Clinical Phase II trial. Successfully produced pilot production of SCO-101 tablets on June 26.
• University of CopenhagencoreStrategic or Co-development Partner · 1 March 2019Collaboration agreement signed regarding co-development of a class of drug candidates that reverts anti-cancer drug resistance. Spinout company from University of Copenhagen and Saniona.
• Biopeople / Boost4Health Interreg ProjectminorStrategic or Co-development Partner · 13 November 2018EU Impact Voucher of 14,999 EUR granted through Biopeople, Denmark's Life Science Cluster, as partner in Boost4Health Interreg project. Supports SCO-101 development in relation to anti-estrogen resistance in breast cancer.
• Herlev-Gentofte HospitalcoreStrategic or Co-development PartnerPrimary clinical trial site for Phase II CORIST trial at Department of Oncology, Herlev Hospital, Copenhagen. Additional oncology departments in Denmark have agreed to participate.
• Professor Josep Tabernero, MD, PhDcoreOthersKey opinion leader (KOL) providing expert commentary on CORIST trial data. KOL interview conducted on the clinical development program.

Scale indicators10 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Aprea Therapeutics: Clinical-stage biotech developing therapies that target cancer cell response pathways, including mechanisms of drug resistance. Comparable as a small-cap oncology company addressing resistance biology with platform potential.
• Cybrexa Therapeutics: Clinical-stage company developing peptide-drug conjugates designed to overcome tumor resistance and improve chemotherapy delivery. Comparable therapeutic approach of combining with chemotherapy to overcome resistance.
• Leap Therapeutics: Clinical-stage oncology company developing therapeutics targeting tumor resistance pathways including TGF-beta and metabolic resistance mechanisms. Comparable focus on overcoming resistance in GI cancers.
• NuCana plc: Clinical-stage oncology company developing phosphoramidate prodrugs designed to overcome cancer drug resistance mechanisms. Most directly comparable to Scandion given shared focus on resistance-reversal in solid tumors and similar clinical-stage profile.

Regional players

• Swedish Orphan Biovitrum (Sobi): Swedish-headquartered specialty pharma focused on rare diseases and oncology with active interest in Nordic biotech licensing and acquisition. Comparable as a regional acquirer profile for a Swedish-listed Danish biotech.
• Vivesto AB: Swedish specialty oncology company developing reformulated chemotherapeutics. Scandion CEO Francois Martelet previously led Vivesto, and the company is a comparable Nordic specialty oncology peer for investor benchmarking.

Emerging players

• Tango Therapeutics: Clinical-stage precision oncology company using synthetic lethality to overcome cancer drug resistance. Comparable as a small-cap biotech applying novel mechanism approaches to resistance biology.
• PetoMac Pharma: Early-stage company developing antibody-drug conjugates targeting cancer drug resistance, with a similar clinical-stage and small-cap Nordic-European operational profile to Scandion.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks2 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/channel/UCZ3qZ9y2xRJ7WraOB1LWs4Q
• Xx.com/Scandion
• LinkedInlinkedin.com/company/scandion-oncology

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scandion Oncology